Navigation Links
BMP Sunstone Reports Second Quarter 2008 Financial Results
Date:8/11/2008

orized as of March 31, 2008 and

December 31, 2007, respectively;

39,492,026 and 31,240,913 Shares

Issued and Outstanding as of March 31,

2008 and December 31, 2007, respectively 40 31

Additional Paid in Capital 157,070 66,123

Common Stock Warrants 9,156 9,747

Accumulated Deficit (31,345) (27,600)

Accumulated Other Comprehensive

Income 8,561 708

Total Stockholders' Equity 143,482 49,009

Total Liabilities and Stockholders'

Equity $226,388 $80,923

Non GAAP Reconciliations

($ amounts, except per share amounts

in thousands)

Three Months Ended June 30,

2008 2007

GAAP Gross Profit $16,561 976

Amortization Related to Acquisition 107 --

Non GAAP Gross Profit $16,668 $976

Three Months Ended June 30,

2008 2007

GAAP Operating Income (Loss) $1,604 $(1,653)

Stock Based Compensation 616 356

Amortization Related to Acquisitions 992 64

Non GAAP Operating Income (Loss) $3,212 $(1,233)

Three Months Ended June 30,

2008 200
'/>"/>

SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
2. BMP Sunstone Receives Import Drug License (IDL) from SFDA
3. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
4. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
8. Par Pharmaceutical Reports Second Quarter 2008 Results
9. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
10. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
11. Isis Reports Financial Results and Highlights for Second Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... proprietary technologies and products for advanced microarray diagnostics, today ... fiscal quarter ended March 31, 2015. ... with our existing customers and to develop new opportunities," ... SQI. "The delivery of a fully automated sqidlite™ system ...
(Date:5/21/2015)... Francisco, CA (PRWEB) May 21, 2015 ... sequencing, has announced a partnership with PicnicHealth, a ... for patients. Participants diagnosed with Inflammatory Bowel Disease ... well as a complementary uBiome research kit. Both ... 2014. , For more information ...
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... Tunnell Consulting, Inc. today ... senior statistician and Principal, a position to which she ... management and analysis of complex and large data sets ... “We’re delighted to have Julia join the Tunnell team ... Dr. Philippe Cini, Group Vice President and leader of ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... June 17 MedPredict has published a,new report ... and,biotech companies with a stake in the market ... report, entitled "Thought Leader Insight &,Analysis: Alzheimer,s Disease," ... of physician thought leaders actively involved in ongoing,research., ...
... June 17 , - First World Allergy ... Increase in Allergies and Allergic Diseases, The ... Report on,the extent of allergy and chronic respiratory ... called for immediate collaboration to tackle the current,escalation ...
... Biomarker ... Industry, PHILADELPHIA and LONDON, June 17 ... for,businesses and professionals, announced today the launch of,BIOMARKERcenter, ... solution will be the first to provide the,pharmaceutical ...
Cached Biology Technology:Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimer's Disease in MedPredict Report 2World Allergy Organization Highlights Global Allergy Impact 2Thomson Reuters Launches New Biomarkers Solution 2
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Australia, the United Kingdom and United States, including University of ... tactics, such as assisted migration, in the face of the ... policy ideas in a paper published July 18 in the ... that both the rapid rate of climate change and the ...
... as they evolve, biologists have unearthed several interesting patterns. ... members of a taxonomic group -- such as the ... elephant are often thousands or millions of times ... time two SFI researchers explain these patterns within an ...
... a close relative of the toadfish, doesn,t need good looks to ... nest for his potential partner, he calls to nearby females by ... buoyancy. The sound he makes is not a song or a ... a ballad. Female midshipman find it very alluring, and they only ...
Cached Biology News:Global warming experts recommend drastic measures to save species 2Predicting the distribution of creatures great and small 2When fish talk, scientists listen 2
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Biology Products: